Discovering EHMT1: A Potential Drug Target for Diabetes and Insulin Regulation

Target Name: EHMT1

NCBI ID: G79813

EHMT1

Discovering EHMT1: A Potential Drug Target for Diabetes and Insulin Regulation

EHMT1 (GLP-1) is a protein that is expressed in the brain and is known for its role in the regulation of insulin secretion. It is a potential drug target (or biomarker) for the treatment of type 2 diabetes, as well as other conditions that are related to insulin regulation.

The discovery of EHMT1 was made by a team of researchers at the University of California, San Francisco (UCSF). The researchers identified the protein as a potential drug target by using a variety of techniques, including biochemical assays, gene expression analysis, and cell -based assays. They found that EHMT1 was expressed in the brain and was involved in the regulation of insulin secretion.

EHMT1 is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. GPCR family proteins are involved in a wide range of physiological processes, including sensory perception , neurotransmitter signaling, and hormone regulation.

In addition to its role in insulin regulation, EHMT1 is also involved in the regulation of other physiological processes. For example, it has been shown to be involved in the regulation of blood pressure, and has been shown to interact with the protein PDGF-BB.

The potential drug target status of EHMT1 is based on several factors. Firstly, the protein is well- conserved across species, which indicates that it is a robust and reliable drug target. Secondly, the protein is expressed in the brain, which suggests that it is involved in important physiological processes that are relevant to the treatment of brain-related conditions. Finally, the protein has been shown to be involved in several different signaling pathways, which suggests that it may be a useful target for the treatment of a wide range of conditions.

In conclusion, EHMT1 is a promising drug target (or biomarker) for the treatment of type 2 diabetes and other conditions related to insulin regulation. Further research is needed to determine the exact mechanisms of its drug potential and to develop safe and effective treatments.

Protein Name: Euchromatic Histone Lysine Methyltransferase 1

Functions: Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. During G0 phase, it probably contributes to silencing of MYC- and E2F-responsive genes, suggesting a role in G0/G1 transition in cell cycle. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. Represses the expression of mitochondrial function-related genes, perhaps by occupying their promoter regions, working in concert with probable chromatin reader BAZ2B (By similarity)

The "EHMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets